ArticleCureus2026
First Clinical Application of Repeated Boron Neutron Capture Therapy for Olfactory Neuroblastoma: Achieving Local Control Despite Regional Progression.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the feasibility and clinical outcomes of two-course boron neutron capture therapy (BNCT) as a salvage treatment for multiply recurrent olfactory neuroblastoma (ONB), and to discuss the implications of intratumoral heterogeneity on treatment planning. A 50-year-old male with recurrent ONB with extensive intracranial invasion underwent BNCT after exhausting surgical and conventional radiotherapy options. Boronophenylalanine (BPA) was administered at 500 mg/kg. The patient received two courses of neutron irradiation at the Tsing Hua Open-Pool Reactor (THOR). Dosimetry was guided by 18F-fluciclovine PET imaging (serving as a surrogate for BPA biodistribution) and calculated using the simulation environment for radiotherapy applications (SERA) treatment planning system. The first BNCT course (April 2024, Tumor Dmax 49.2 Gy-Eq) resulted in significant tumor shrinkage; however, PET imaging revealed residual metabolic activity in centrally necrotic regions. Consequently, a second BNCT course was administered (March 2025, Tumor Dmax 40.73 Gy-Eq). The patient achieved a near-complete response at the primary skull base site with no high-grade adverse effects. Although local control was sustained as of November 2025, a new cervical lymph node metastasis was identified. BNCT serves as a potent and safe salvage modality for recurrent, radio-resistant ONB, allowing for high tumor doses while sparing critical brain structures. The discordant response between the tumor rim and necrotic core highlights the challenge of heterogeneity, supporting the rationale for fractionated BNCT protocols and careful surveillance of regional nodal basins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.